Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Tuberculosis: pathogenesis, current treatment regimens and new drug targets
Mycobacterium tuberculosis (M. tb), the causative agent of TB, is a recalcitrant pathogen that
is rife around the world, latently infecting approximately a quarter of the worldwide …
is rife around the world, latently infecting approximately a quarter of the worldwide …
Antibiotics in the clinical pipeline as of December 2022
The need for new antibacterial drugs to treat the increasing global prevalence of drug-
resistant bacterial infections has clearly attracted global attention, with a range of existing …
resistant bacterial infections has clearly attracted global attention, with a range of existing …
Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed
There is an urgent global need for new strategies and drugs to control and treat multidrug-
resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of …
resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of …
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis
Antibacterial agents target the products of essential genes but rarely achieve complete
target inhibition. Thus, the all-or-none definition of essentiality afforded by traditional genetic …
target inhibition. Thus, the all-or-none definition of essentiality afforded by traditional genetic …
Tuberculosis drug discovery: challenges and new horizons
Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …
Antibiotics in the clinical pipeline in October 2019
The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR)
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …
Strategies to combat multi-drug resistance in tuberculosis
Conspectus “Drug resistance is an unavoidable consequence of the use of drugs; however,
the emergence of multi-drug resistance can be managed by accurate diagnosis and tailor …
the emergence of multi-drug resistance can be managed by accurate diagnosis and tailor …
Antibacterial drug discovery in the resistance era
The looming antibiotic-resistance crisis has penetrated the consciousness of clinicians,
researchers, policymakers, politicians and the public at large. The evolution and widespread …
researchers, policymakers, politicians and the public at large. The evolution and widespread …
Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587
Y Zhang, Y Lai, S Zhou, T Ran, Y Zhang, Z Zhao… - Nature, 2024 - nature.com
Abstract Bedaquiline (BDQ), a first-in-class diarylquinoline anti-tuberculosis drug, and its
analogue, TBAJ-587, prevent the growth and proliferation of Mycobacterium tuberculosis by …
analogue, TBAJ-587, prevent the growth and proliferation of Mycobacterium tuberculosis by …
Hit and lead criteria in drug discovery for infectious diseases of the develo** world
Reducing the burden of infectious diseases that affect people in the develo** world
requires sustained collaborative drug discovery efforts. The quality of the chemical starting …
requires sustained collaborative drug discovery efforts. The quality of the chemical starting …